Y. Dai et al. / Journal of Organometallic Chemistry 696 (2012) 4309e4314
4313
138.4, 136.8, 136.7, 134.1, 133.9, 133.0, 129.6, 128.33, 128.30, 128.2,
124.8, 121.6, 121.6, 54.1, 26.1, 24.2.; 31P NMR (162 MHz, CDCl3):
4.4.2. 1-(2-(Diphenylphosphino)phenyl)-4-methylpiperazine (L4)
L4 was prepared similarly as L3 using 1-methylpiperazine
(150 mg, 1.5 mmol) as a starting material (L4: 339 mg, 94% yield,
yellow crystal).
d
ꢃ11.23; IR (KBr) 3051, 2938, 2850, 2797, 1579, 1466, 1433, 1224,
922þ, 765, 740, 696 cmꢃ1; HRMS (EI) calcd. for C23H24NP: 345.1646
[M] ; found: 345.1652; m.p.: 96e98 ꢁC.
1H NMR (400 MHz, CDCl3)
d
7.33e7.28 (m, 11H), 7.20e7.17 (m,
1H), 7.03 (t, J ¼ 7.4 Hz, 1H), 6.73e6.70 (m, 1H), 2.87 (t, J ¼ 4.6 Hz,
4H), 2.46e2.01 (m, 7H).; 13C NMR (101 MHz, CDCl3):
155.8, 155.6,
4.3.2. 4-(2-(Diphenylphosphino)phenyl)morpholine (L2)
L2 was prepared similarly as L1 using BPMP (2.66 g, 11 mmol) as
a starting material (L2: 2.36 g, 68% yield, white crystal).
d
138.2, 138.1, 136.8, 136.7, 134.2, 134.0, 133.2, 129.8, 128.5, 128.43,
128.35, 125.4, 121.9, 55.2, 52.3, 46.1.; 31P NMR (162 MHz, CDCl3):
1H NMR (400 MHz, CDCl3)
d
7.33e7.30 (m, 11H), 7.17e7.14 (m,
d
ꢃ12.01; IR (KBr) 3052, 2936, 2795, 1579, 1466, 1434, 1369, 1287,
1H), 7.03 (t, J ¼ 7.5 Hz, 1H), 6.75e6.72 (m, 1H), 3.48 (t, J ¼ 4.2 Hz,
1226, 1146, 1009, 927, 909, 768, 740, 742, 697 cmꢃ1; HRMS (EI)
calcd. for C23H25N2P: 360.1755 [M]þ; found: 360.1750, m.p.:
106e107 ꢁC.
4H), 2.80 (t, J ¼ 4.5 Hz, 4H).; 13C NMR (101 MHz, CDCl3):
d 155.4,
155.3, 138.0, 137.9, 136.94, 136.86, 134.2, 134.0, 133.2, 129.8, 128.6,
128.4, 128.3, 125.5, 121.8, 121.7, 67.2, 52.8, 52.8.; 31P NMR (162 MHz,
CDCl3)
d
ꢃ3.97; IR (KBr) 3052, 2956, 2853, 2814, 1580, 1466, 1433,
4.4.3. 4-(2-(Diphenylphosphino)phenyl)-3,4-dihydro-2H-benzo[b]
[1,4]oxazine (L5)
1219, 1113, 932, 767, 742, 697 cmꢃ1
; HRMS (EI) calcd. for
C22H22NOP: 347.1439 [M]þ; found: 347.1440; m.p.: 116e118 ꢁC.
L5 was prepared similarly as L3 using 3,4-dihydro-2H-1,4-
benzoxazine (203 mg, 1.5 mmol) as a starting material and
(ꢀ)-BINAP (37 mg, 0.06 mmol) as a ligand. The crude product was
purified by chromatography (5:100 ethyl acetate/petroleum ether)
to give L5 (172 mg, 44% yield) as a white crystal, and 36% of starting
material BDPP was recovered.
4.3.3. 4,40-((Phenylphosphinediyl)bis(2,1-phenylene))dimorpholine
(L6)
L6 was prepared similarly as L2 using BPMP (5.32 g, 22 mmol) as
a starting material (L6: 2.42 g, 56% yield, white crystal).
1H NMR (400 MHz, CDCl3)
d
7.33e7.31 (m, 7H), 7.17e7.14 (m,
1H NMR (400 MHz, CDCl3)
d 7.42e7.21 (m, 13H), 6.98e6.96 (m,
2H), 7.00 (t, J ¼ 7.4 Hz, 2H), 6.70 (d, J ¼ 7.4 Hz, 2H), 3.59e3.52 (m,
1H), 6.78e6.76 (m, 1H), 6.65e6.56 (m, 2H), 6.14e6.13 (m, 1H), 4.07
(d, J ¼ 10.7 Hz, 1H), 3.97 (t, J ¼ 9.7 Hz, 1H), 3.53e3.48 (m, 1H), 3.06
8H), 2.92e2.89 (m, 4H), 2.85e2.82 (m, 4H); 13C NMR (101 MHz,
CDCl3):
129.5, 128.4, 128.3, 128.2, 125.0, 121.1, 67.3, 53.0, 52.9; 31P NMR
(162 MHz, CDCl3):
d
155.7, 155.5, 138.8, 138.7, 137.1, 137.0, 134.6, 134.4, 133.6,
(d, J ¼ 11.1 Hz,1H).; 13C NMR (101 MHz, CDCl3):
d 150.2, 150.0, 144.3,
139.4,139.3,137.1,137.0,136.7,136.5,134.6,134.3,134.0,130.7,128.9,
128.7, 128.6, 128.5, 128.4, 128.0, 127.4, 120.9, 119.0, 116.3, 115.7, 64.5,
d
ꢃ19.69; IR (KBr) 3347, 3053, 2957, 2853, 2814,
1580, 1466, 1445, 1371, 1263, 1219, 1113, 932, 919, 847, 768, 735,
699 cmꢃ1; HRMS (EI) calcd. for C26H29N2O2P: 432.1967 [M]þ;
found: 432.1973; m.p.: 153e154 ꢁC.
49.0.; 31P NMR (162 MHz, CDCl3):
2841, 1604, 1582, 1497, 1463, 1434, 1314, 1242, 1057, 909, 795, 767,
740, 697 cmꢃ1; HRMS (EI) calcd. for C26H22NOP: 395.1439 [M]þ;
found: 395.1449; m.p.: 130e131 ꢁC.
d
ꢃ13.95; IR (KBr) 3053, 2977,
4.3.4. Tris(2-morpholinophenyl)phosphine (L7)
L7 was prepared similarly as L2 using BPMP (7.98 g, 33 mmol) as
a starting material (L7: 2.64 g, 51% yield, white crystal).
4.5. Synthesis of the Pd(II) complexes C1 and C2
1H NMR (400 MHz, CDCl3)
d
7.32e7.28 (m, 3H), 7.15e7.12 (m,
3H), 6.98e6.94 (m, 3H), 6.71e6.68 (m, 3H), 3.61 (s, 12H), 3.15 (s,
6H), 2.69 (s, 6H).; 13C NMR (101 MHz, CDCl3):
156.1, 155.9, 137.0,
136.9, 134.3, 129.4, 124.8, 120.43, 120.41, 67.4, 53.1.; 31P NMR
(162 MHz, CDCl3):
4.5.1. 1-(2-(Diphenylphosphino)phenyl)piperidine Pd(II) dichloride
(C1)
d
L1 (173 mg, 0.5 mmol), PdCl2(MeCN)2 (130 mg, 0.5 mmol), and
CHCl3 (5 mL) were mixed in a Schlenk reactor at room temperature.
The reaction mixture was stirred for 1 h, filtered, and evaporated in
vacuo. The residue obtained was washed with ethanol to give C1
(237 mg, 91% yield) as a yellow powder.
d
ꢃ19.69; IR (KBr) 3051, 2956, 2851, 2812, 1580,
1466, 1444, 1370, 1295, 1253, 1220, 1113, 932, 919, 846, 768,
735 cmꢃ1; HRMS (EI) calcd. for C30H36N3O3P: 517.2494 [M]þ; found:
517.2495; m.p.: 242e244 ꢁC.
1H NMR (400 MHz, CDCl3)
d 8.19e8.15 (m, 1H), 7.82e7.77 (m,
4.4. Synthesis of ligands L3eL5
4H), 7.65e7.56 (m, 3H), 7.49e7.35 (m, 6H), 5.52e5.45 (m, 2H), 3.34
(d, J ¼ 13.2 Hz, 2H), 2.17e2.01 (m, 4H),1.70 (d, J ¼ 13.6 Hz, 2H); 13C
4.4.1. 1-(2-(Diphenylphosphino)phenyl)piperazine (L3)
NMR (101 MHz, CDCl3): d 160.4, 160.3, 134.7, 133.9, 133.8, 133.6,
BDPP (341 mg, 1 mmol), NaOtBu (114 mg, 1.5 mmol), piperazine
(129 mg, 1.5 mmol), Pd2(dba)3 (9 mg, 0.01 mmol), L7 (31 mg,
0.06 mmol), and toluene (2.5 mL) were mixed in a Schlenk reactor.
After the reaction mixture was placed in a pre-heated oil bath at
100 ꢁC for 24 h, H2O (20 mL) was added at room temperature. The
product was extracted with ether (10 mL ꢂ 3) and was dried over
Na2SO4. The solvent was evaporated in vacuo. The remaining solid
was purified by chromatography (5:100 methanol/dichloro-
methane) to give L3 (249 mg, 72% yield) as a yellow crystal along
with a debrominated product (PPh3, 25%).
132.3, 130.1, 129.6, 129.4, 129.2, 129.1, 128.2, 127.6, 126.2, 126.1, 60.7,
22.7, 21.1.; 31P NMR (162 MHz, CDCl3):
39.82; IR (KBr) 3447, 3056,
2940, 2877, 2797, 1579, 1477, 1464, 1435, 1101, 911, 729, 690 cmꢃ1
d
;
Anal. calcd. for C23H24Cl2NPPd: C, 52.85; H, 4.63; N, 2.68. Found: C,
51.95; H, 4.68; N, 2.40; m.p.: 204 ꢁC, decomposed.
4.5.2. 4-(2-(Diphenylphosphino)phenyl)morpholine Pd(II)
dichloride (C2)
C2 was prepared similarly as C1 using L2 (174 mg, 0.5 mmol) as
a ligand instead of L1 (C2: 245 mg, 94% yield, yellow powder).
1H NMR (400 MHz, CDCl3)
1H), 7.04 (t, J ¼ 7.5 Hz, 1H), 6.72e6.69 (m, 1H), 2.82 (t, J ¼ 4.5 Hz,
4H), 2.69e2.68 (m, 4H).; 13C NMR (101 MHz, CDCl3):
156.0, 155.8,
138.1, 138.0, 136.84, 136.76, 134.1, 133.9, 133.0, 129.7, 128.5, 128.4,
128.3, 125.3, 121.8, 53.4, 45.9.; 31P NMR (162 MHz, CDCl3):
d
7.34e7.28 (m, 11H), 7.18e7.15 (m,
1H NMR (400 MHz, CDCl3)
d 8.21e8.18 (m, 1H), 7.82e7.76 (m,
4H), 7.71e7.69 (m, 1H), 7.61e7.57 (m, 2H), 7.50e7.46 (m, 4H),
7.44e7.37 (m, 2H), 5.36e5.31 (m, 2H), 4.30e4.26 (m, 2H),
4.02e3.97 (m, 2H), 3.40e3.37 (m, 2H); 13C NMR (101 MHz, CDCl3):
d
d
ꢃ11.72;
d
160.1, 156.0, 134.4, 133.8, 133.7, 132.5, 129.5, 129.4, 129.3, 129.2,
129.0, 127.8, 127.1, 126.6, 126.5, 61.9, 59.5.; 31P NMR (162 MHz,
CDCl3): 38.65; IR (KBr) 3056, 2956, 2883, 1579, 1480, 1436, 1102,
910, 727, 690 cmꢃ1; Anal. calcd. for C22H22Cl2NOPPd: C, 50.36; H,
IR (KBr) 3281, 3052, 2942, 2817, 1580, 1466, 1434, 1371, 1219, 1316,
1220, 937, 909, 767, 739, 742, 697 cmꢃ1; HRMS (EI) calcd. for
C22H23N2P: 346.1599 [M]þ; found: 346.1610; m.p.: 98e100 ꢁC.
d